(NASDAQ: BBNX) Beta Bionics's forecast annual revenue growth rate of 31.36% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.99%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.71%.
Beta Bionics's revenue in 2026 is $110,238,000.On average, 13 Wall Street analysts forecast BBNX's revenue for 2026 to be $6,026,523,632, with the lowest BBNX revenue forecast at $5,681,616,113, and the highest BBNX revenue forecast at $6,306,371,076. On average, 13 Wall Street analysts forecast BBNX's revenue for 2027 to be $8,113,347,809, with the lowest BBNX revenue forecast at $6,987,273,776, and the highest BBNX revenue forecast at $9,077,217,272.
In 2028, BBNX is forecast to generate $11,376,600,734 in revenue, with the lowest revenue forecast at $9,939,486,070 and the highest revenue forecast at $13,241,507,669.